Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
To read the full story
Related Article
- LDP Study Group Submits Proposal for FY2024 Reform, Urges Boosted Drug Price Premiums at Launch
November 21, 2023
- LDP Pharma Study Group Calls for Expanding Sakigake Premium, Creating New Premium
November 15, 2023
- Hopes to Nix Budget Ceiling Dashed, How Will Industry Get Its Message Across to Govt?
September 4, 2023
- Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
- Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
- LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
- Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
- LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
- LDP Pharma Study Group to Draw Up Resolution in May before Honebuto Paper
April 13, 2023
REGULATORY
- 12 Quasi-Original Drugs to Be Excluded from New Coverage Scheme
April 23, 2024
- Japan Wants to See Positive Trends on Drug Development after Reform: Official
April 23, 2024
- Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024
- Japan Commences Project to Provide Telemedicine Services at Post Offices
April 22, 2024
- MHLW Proposes Simplified Generic Delisting Scheme
April 22, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…